GENFIT Reports Strong 2025 Revenue but Faces Rising Costs
Event summary
- GENFIT reported €65.4 million in revenue for 2025, including €43.6 million in milestones and €21.8 million in royalties from Ipsen.
- Cash and cash equivalents totaled €101.1 million as of December 31, 2025, with a cash runway extending beyond the end of 2028.
- Ipsen's Iqirvo® achieved €208 million in net sales for 2025, triggering a €20 million commercial milestone payment to GENFIT.
- GENFIT recorded a net loss of €86.0 million for 2025, compared to a net gain of €1.5 million in 2024.
- Phase 2 initiation for NTZ in ACLF and GNS561 in CCA is targeted for the second half of 2026.
The big picture
GENFIT's 2025 financial results highlight the company's reliance on Ipsen's commercial success with Iqirvo®, which drove significant milestone and royalty revenue. However, rising R&D costs and a substantial net loss underscore the challenges of balancing growth with financial sustainability. The company's strategic focus on ACLF and CCA clinical trials, along with its diagnostic technology in MASH, positions it within the broader trend of targeting rare and life-threatening liver diseases. The ability to sustain this trajectory will depend on the success of its pipeline and the continued performance of its partnerships.
What we're watching
- Royalty Growth
- Whether Ipsen's strong performance with Iqirvo® will continue to drive significant royalty revenue for GENFIT.
- Clinical Development
- The pace at which GENFIT can advance its Phase 2 studies for NTZ in ACLF and GNS561 in CCA.
- Financial Flexibility
- How GENFIT will manage its rising R&D costs and maintain its cash runway beyond 2028.
Related topics